Stockreport

Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the First and Only Approved Medicine for FSGS

Travere Therapeutics, Inc.  (TVTX) 
PDF FILSPARI indicated to reduce proteinuria in adults and children aged 8 years and older with FSGS who do not have nephrotic syndromeAdditional indication for FILSPARI exp [Read more]